Prognostic effect of preoperative systemic immune-inflammation index in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma

被引:12
|
作者
Laukhtina, Ekaterina [1 ,2 ]
Pradere, Benjamin [1 ,3 ]
D'Andrea, David [1 ]
Rosiello, Giuseppe [4 ,5 ,6 ]
Luzzago, Stefano [4 ,7 ]
Pecoraro, Angela [4 ,8 ]
Palumbo, Carlotta [4 ,9 ,10 ]
Knipper, Sophie [4 ,11 ]
Karakiewicz, Pierre, I [4 ]
Margulis, Vitaly [12 ]
Quhal, Fahad [1 ,13 ]
Sari Motlagh, Reza [1 ]
Mostafaei, Hadi [1 ,14 ]
Mori, Keiichiro [1 ,15 ]
Schuettfort, Victor M. [1 ,16 ]
Enikeev, Dmitry [2 ]
Shariat, Shahrokh F. [1 ,2 ,12 ,17 ,18 ,19 ,20 ,21 ]
机构
[1] Med Univ Vienna, Comprehens Canc Ctr, Dept Urol, Vienna, Austria
[2] Sechenov Univ, Inst Urol & Reprod Hlth, Moscow, Russia
[3] Univ Hosp Tours, Dept Urol, Tours, France
[4] Univ Montreal Hlth Ctr, Div Urol, Canc Prognost & Hlth Outcomes Unit, Montreal, PQ, Canada
[5] IRCCS San Raffaele Sci Inst, Dept Urol, Milan, Italy
[6] IRCCS San Raffaele Sci Inst, Div Expt Oncol, Urol Res Inst URI, Milan, Italy
[7] IRCCS, Dept Urol, European Inst Oncol, Milan, Italy
[8] Univ Turin, San Luigi Gonzaga Hosp, Dept Urol, Turin, Italy
[9] ASST Spedali Civili Brescia, Dept Med & Surg Specialties, Urol Unit, Brescia, Italy
[10] Univ Brescia, Radiol Sci & Publ Hlth, Brescia, Italy
[11] Univ Hosp Hamburg Eppendorf, Martini Klin Prostate Canc Ctr, Hamburg, Germany
[12] Univ Texas Southwestern Med Ctr Dallas, Dept Urol, Dallas, TX 75390 USA
[13] King Fahad Specialist Hosp, Dept Urol, Dammam, Saudi Arabia
[14] Tabriz Univ Med Sci, Res Ctr Evidence Based Med, Tabriz, Iran
[15] Jikei Univ, Dept Urol, Sch Med, Tokyo, Japan
[16] Univ Med Ctr Hamburg Eppendorf, Dept Urol, Hamburg, Germany
[17] Weill Cornell Med Coll, Dept Urol, New York, NY USA
[18] Charles Univ Prague, Fac Med 2, Dept Urol, Prague, Czech Republic
[19] Karl Landsteiner Inst Urol & Androl, Vienna, Austria
[20] Univ Jordan, Jordan Univ Hosp, Dept Special Surg, Div Urol, Amman, Jordan
[21] European Assoc Urol Res Fdn, Arnhem, Netherlands
来源
MINERVA UROLOGY AND NEPHROLOGY | 2022年 / 74卷 / 03期
关键词
Renal cell carcinoma; Neoplasm metastasis; Cytoreduction surgical procedures; Nephrectomy; Survival; Mortality; LYMPHOCYTE RATIO; SURVIVAL; MODEL;
D O I
10.23736/S2724-6051.21.04023-6
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Identifying those of patients with metastatic renal cell carcinoma (mRCC) who are most likely to benefit from cytoreductive nephrectomy (CN) is challenging. We tested the association between preoperative value of Systemic Immune-Inflammation Index (SII) and overall survival (OS) as well as cancer-specific survival (CSS) in mRCC patients treated with CN. METHODS: mRCC patients treated with CN at different institutions were included. After assessing for the optimal pretreatment SII cut-off value, we found 710 to have the maximum Youden Index value. The overall population was therefore divided into two SII groups using this cut-off (low, <710 vs. high, >= 710). Univariable and multivariable Cox regression analyses tested the association SII and OS as well as CSS. The discrimination of the model was evaluated with the Harrel's Concordance Index (C-Index). The clinical value of the SII was evaluated with decision curve analysis (DCA). RESULTS: Among 613 mRCC patients, 298 (49%) patients had a SII>710. Median follow-up was 31 (IQR 16-58) months. On univariable analysis, high preoperative serum SII was significantly associated with worse OS (HR: 1.28, 95% CI: 1.07-1.54, P=0.01) and CSS (HR: 1.29, 95% CI: 1.08-1.55, P=0.01). On multivariable analysis, which adjusted for the effect of established clinicopathologic features, SII >= 710 was associated with OS (HR: 1.25, 95% CI: 1.04-1.50, P=0.02) and CSS (HR: 1.26, 95% CI: 1.05-1.52, P=0.01). The addition of SII only slightly improved the discrimination of a base model that included established clinicopathologic features (C-index: 0.637 vs. 0.629). On DCA, the inclusion of SII did not improve the net-benefit of the prognostic model. On multivariable analyses, SII >= 710 remained independently associated with the worse OS and CSS in IMDC intermediate risk group (both: HR: 1.31, 95% CI: 1.02-1.67, P=0.03). In the subgroup analyses based on the BMI, among patients with BMI 25, SII was significantly associated with OS (HR: 1.29., 95% CI: 1.04-1.61, P=0.02) and CSS (HR: 1.31, 95% CI: 1.05-1.63, P=0.02). CONCLUSIONS. We found an independent association of high SII prior to CN with unfavorable clinical outcomes, particularly in patients with intermediate risk mRCC and patients with increased BMI. Despite these results, it does not seem to add any prognostic or clinical benefit beyond that obtained by currently available clinicopathologic characteristics as sole worker.
引用
收藏
页码:329 / 336
页数:8
相关论文
共 50 条
  • [21] Role of the Systemic Immune-Inflammation Index in Patients with Metastatic Renal Cell Carcinoma Treated with First-Line Ipilimumab plus Nivolumab
    Stuhler, Viktoria
    Herrmann, Lisa
    Rausch, Steffen
    Stenzl, Arnulf
    Bedke, Jens
    CANCERS, 2022, 14 (12)
  • [22] Prognostic Value of Preoperative Systemic Immune-Inflammation Index in Patients with Cervical Cancer
    Huang, Huaping
    Liu, Qin
    Zhu, Lixia
    Zhang, Yan
    Lu, Xiaojuan
    Wu, Yawei
    Liu, Li
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [23] Prognostic significance of the preoperative systemic immune-inflammation index in patients with oral cavity squamous cell carcinoma treated with curative surgery and adjuvant therapy
    Hung, Sheng-Ping
    Chen, Pei-Rung
    Ho, Tsung-Ying
    Chang, Kai-Ping
    Chou, Wen-Chi
    Lee, Ching-Hsin
    Wu, Yao-Yu
    Chen, Po-Jui
    Lin, Chia-Hsin
    Chou, Yung-Chih
    Fan, Kang-Hsing
    Lin, Chien-Yu
    Huang, Bing-Shen
    Tung-Chieh Chang, Joseph
    Wang, Chun-Chieh
    Tsang, Ngan-Ming
    CANCER MEDICINE, 2021, 10 (02): : 649 - 658
  • [24] Prognostic Value of Preoperative Systemic Immune-Inflammation Index in Non-Metastatic Paediatric Wilms Tumour Patients Undergoing Upfront Radical Nephrectomy
    Sai, Kai
    Ding, Yi-Bo
    Gao, Qun
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2024, 34 (11): : 1327 - 1333
  • [25] Systemic immune-inflammation index to predict the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.
    Lolli, Cristian
    Maruzzo, Marco
    Derosa, Lisa
    Sava, Teodoro
    Santoni, Matteo
    Massari, Francesco
    Wheater, Matthew James
    Aieta, Michele
    Scarpi, Emanuela
    La Russa, Francesca
    Crabb, Simon J.
    Cascinu, Stefano
    Galli, Luca
    Basso, Umberto
    De Giorgi, Ugo
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [26] Prognostic model of upfront cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors and/or targeted agents
    Jun Teishima
    Keisuke Goto
    Yohei Sekino
    Koji Mita
    Tetsutaro Hayashi
    Yasuhisa Hasegawa
    Masao Kato
    Mitsuru Kajiwara
    Masanobu Shigeta
    Satoshi Maruyama
    Yuichi Kadonishi
    Seiji Fujiwara
    Kanao Kobayashi
    Kousuke Asano
    Nobuyuki Hinata
    International Urology and Nephrology, 2022, 54 : 1225 - 1232
  • [27] Prognostic model of upfront cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors and/or targeted agents
    Teishima, Jun
    Goto, Keisuke
    Sekino, Yohei
    Mita, Koji
    Hayashi, Tetsutaro
    Hasegawa, Yasuhisa
    Kato, Masao
    Kajiwara, Mitsuru
    Shigeta, Masanobu
    Maruyama, Satoshi
    Kadonishi, Yuichi
    Fujiwara, Seiji
    Kobayashi, Kanao
    Asano, Kousuke
    Hinata, Nobuyuki
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2022, 54 (06) : 1225 - 1232
  • [28] Association of preoperative systemic Immune-inflammation Index and Prognostic Nutritional Index with survival in patients with Upper Tract Urothelial Carcinoma
    Zheng, Yangqin
    Yu, Dongdong
    Yu, Zhixian
    Zhao, Dewei
    Chen, Yuming
    Chen, Wu
    Li, Yeping
    Lin, Binwei
    Gao, Xiaomin
    JOURNAL OF CANCER, 2020, 11 (19): : 5665 - 5677
  • [29] Cytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint Therapy
    Hahn, Andrew W.
    Kotecha, Ritesh R.
    Viscuse, Paul V.
    Pieretti, Alberto C.
    Wiele, Andrew J.
    Jonasch, Eric
    Lee, Chung-Han
    Gao, Jianjun
    Zurita, Amado J.
    Shah, Amishi Y.
    Campbell, Matthew T.
    Sharma, Padmanee
    Motzer, Robert J.
    Russo, Paul
    Wood, Christopher G.
    Tannir, Nizar M.
    Voss, Martin H.
    Karam, Jose A.
    Hakimi, A. Ari
    Msaouel, Pavlos
    EUROPEAN UROLOGY FOCUS, 2023, 9 (05): : 734 - 741
  • [30] Preoperative systemic immune-inflammation index predicts prognosis of patients with non-metastatic renal cell carcinoma: a propensity score-matched analysis
    Hu, Xu
    Shao, Yan-Xiang
    Yang, Zhi-Qiang
    Dou, Wei-Chao
    Xiong, San-Chao
    Li, Xiang
    CANCER CELL INTERNATIONAL, 2020, 20 (01)